Merck not responsible in Illinois Vioxx case

Share this article:
An Illinois jury Tuesday ruled Merck’s withdrawn painkiller Vioxx was not responsible for causing a 52-year-old woman’s fatal heart attack and awarded no damages in the case. Plaintiff Frank Schwaller sued Merck after his wife Patricia, took Vioxx for 20 months for shoulder pain before dying from a heart attack in August 2003. Schwaller’s lawyers alleged that Vioxx was defectively designed, inadequately tested, dangerous to human health, and lacked proper warnings, which subjected users to risks of heart attack, stroke and other illnesses. Merck argued Mrs. Schwaller’s preexisting risk factors – a family history of heart disease, morbid obesity, diabetes, high blood pressure, and sedentary lifestyle – were responsible for her sudden cardiac death. “The combination of these risk factors put her at increased risk for sudden cardiac death, having nothing to do with Vioxx,” said Dan Ball of the St. Louis firm Bryan Cave LLP, Merck's lead attorney in the case. In trials that have reached a jury verdict, Merck, so far, has won 10 and lost five.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...